Podcasts about annual meetings

On this episode of Diabetes Connections In the news… The FDA approves a new indication and health benefit for Mounjaro, lots of CGM news including an update on Medicare coverage for people who don't use insulin and a new study about using CGM when you don't have diabetes, metformin and aging, statins and type 2, and did you know there was a Dolly Parton diabetes connections? That and much more... Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  On this episode of Diabetes Connections In the news… The FDA approves a new indication and health benefit for Mounjaro, lots of CGM news including an update on Medicare coverage for people who don't use insulin and a new study about using CGM when you don't have diabetes, metformin and aging, statins and type 2, and did you know there was a Dolly Parton diabetes connections? That and much more.. that's coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Welcome to September! Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved – more on that coming up. But please register – the link is in the show notes. So much going on over here – tomorrow night we have our Club 1921 in Charlotte, later this month Moms' Night Out Detroit/Bloomfield and in October we're going to Seattle. Please join us. More at d-c dot com slash events. Okay.. our top story this week: XX Another indication for Mounjaro – the FDA approved it to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk for these events. Mounjaro – the brand name of tirzepatide - is already approved as an adjunct to diet and exercise to improve blood sugar in adults and children 10 years of age and older with type 2 diabetes. The approval was based on results from the largest and longest tirzepatide study to date, enrolling more than 13,000 participants across 30 countries over more than four and a half years. In the trial, Mounjaro demonstrated non-inferiority to Trulicity (dulaglutide), a GLP-1 treatment with established cardiovascular benefit, with an 8% lower rate of cardiovascular death, heart attack or stroke (MACE-3). The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for Mounjaro compared to Trulicity (dulaglutide). https://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes-302862415.html XX The FDA approves the Libre Duo – the first device designed to continuously monitor both blood sugar levels and ketone levels in people with diabetes. The Libre Duo 10-Day Continuous Dual Glucose Ketone Monitoring System is now approved for those ages 2 and older. Until now, the agency said, people had to monitor ketone levels with separate tests that only provided a single measurement at one point in time. The new system combines blood sugar and ketone tests and monitors them continuously. Readings -- and alerts in case of dangerous trends -- are sent wirelessly to a smartphone app. The FDA previously granted "breakthrough device" status to the system, which is meant to expedite the device's development and review. https://www.upi.com/Top_News/US/2026/08/25/fda-oks-blood-sugar-ketone-monitor/5521787688375/ XX Diabetes tech firms Dexcom and Abbott are watching closely for a Medicare coverage expansion that could significantly broaden access to their glucose sensors. The Centers for Medicare and Medicaid Services is expected to expand Medicare coverage of continuous glucose monitors to people with diabetes who do not take insulin. Currently, coverage is limited to people with Type 1 or Type 2 diabetes who take insulin or have a history of problematic low blood sugar. Dexcom CEO Jake Leach told investors in a late July earnings call that the company expects to hear back from the CMS before the end of the year, with coverage going into effect in mid-2027.     Dexcom presented results of a randomized, controlled trial earlier this summer at the American Diabetes Association's Scientific Sessions that it expects will support the CMS' decision. The 26-week study found that people who used a CGM had a larger hemoglobin A1C reduction than the control group and spent five more hours per day in a normal glucose range than the control group. https://www.medtechdive.com/news/dexcom-abbott-await-medicare-coverage-expansion-for-cgms/828775/ XX A new study suggests continuous glucose monitors (CGMs) may offer benefits for people with type 1 diabetes that go beyond improving blood sugar and reducing hypoglycemia.   Researchers analyzed health records from more than 8,400 adults with type 1 diabetes receiving care through the Veterans Health Administration. Over one to four years of follow-up, people who started using a CGM had a 10% to 16% lower risk of death from any cause compared with those who did not use one.   The association appeared strongest among people over age 65 and those who were not using insulin pumps. Researchers did not find meaningful differences based on A1C, race or ethnicity, or frailty.   Importantly, this was an observational study using medical records, not a randomized clinical trial, so it cannot prove that CGM use directly caused the lower death rate. But the findings suggest CGM may have important long-term health benefits beyond glucose management.https://visualize.jove.com/42319755-continuous-glucose-monitoring-initiation-is-associated-with-reduced-mortality-in-older-onset-type-1-diabetes-patients-a-target-trial-emulation-study-within-the-veterans-health-administration XX We've been talking about people without diabetes using CGMs for a long time.. now a new study weighs in. Research published in JAMA finds that this wellness trend isn't helpful for people without a diabetes diagnosis. They found that the strongest evidence for CGM use is for people who are already living with diabetes, but not for those without the condition who use them for wellness purposes. It's also worth noting, though, that this new study is a narrative review. This means that the researchers drew their conclusions from the findings reported in several other studies. More randomized controlled trials would be necessary to see whether there are any meaningful health benefits of using a CGM if you don't have diabetes.   Dower also warned that constantly monitoring your blood sugar when you don't have diabetes could lead to unintended health anxiety. In some cases, you may even make accidental lifestyle changes that could be harmful. "[Blood sugar] spikes may occur after meals, but if this leads someone to replace healthy food such as fruit with unhealthy food such as something high in fat but low in carbohydrate, the glucose information has done more harm than good," Dower said. https://www.verywellhealth.com/blood-sugar-monitor-for-people-without-diabetes-12058575   XX   Could metformin somehow influence the biological processes that drive aging? A new review found evidence that metformin may affect several key features of aging, including how cells use energy, inflammation, cellular damage and even some changes in gene activity. Animal studies have shown longer lifespans or improvements in markers of biological aging, while some human studies have also found promising results.   But researchers say there's still no proof that metformin actually slows aging or helps healthy people live longer. Most human research has involved people with diabetes or other health conditions, and one large trial found that while metformin helped prevent type 2 diabetes, it did not reduce cancer, cardiovascular disease or deaths.   Researchers say larger clinical trials in people without diabetes are needed to determine whether metformin can truly extend healthy lifespan—or whether its benefits are primarily related to preventing and treating specific diseases. https://www.technologynetworks.com/drug-discovery/news/metformin-may-influence-longevity-through-the-gut-microbiome-and-epigenetic-changes-416035 XX More to come including more research on a spice thought to help diabetes, predictions about the number of people who may be living with type 1 in the years to come around the world, and a connection I didn't know about between diabetes and Dolly Parton.   XX A compound found in turmeric may help protect blood vessels from some of the damage caused by Type 1 diabetes. In rats, curcumin reduced inflammation, improved cellular signaling, and restored vascular health to levels resembling those of nondiabetic animals. The results hint at a possible new way to reduce the long-term cardiovascular risks of diabetes, but human trials are still needed. Curcumin, the natural compound responsible for turmeric's vivid yellow color, is widely studied for its anti-inflammatory and antioxidant properties. https://www.sciencedaily.com/releases/2026/08/260824065543.htm XX New research estimates the number of people living with type 1 diabetes (T1D) worldwide will increase by 29% from 9.4 million in 2025 to 12.1 million in 2049. This will be presented at EASD, the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2 The USA will see an increase of over half a million, going from 1,492,825 to 2,055,235. The authors suggest that the reasons for the predicted high incidence and prevalence in 2049 in countries such as Australia, US, UK are likely to be a combination of genetics, environmental triggers and also high case detection rates (due to the good health care infrastructure here and in other HIC). Unlike previous estimates, the DIAMOND-T1D model takes historical patterns of insulin availability into account and aims to provide global, regional and country-specific estimates of T1D incidence, prevalence and mortality from 1900 to 2050. Although the majority of people with T1D live in high-income countries (HIC) and middle-income countries (MIC), the largest relative increase in the T1D prevalence is expected to occur in LIC as access to insulin, glucose monitoring and survival all improve in those countries. https://www.news-medical.net/news/20260828/Type-1-diabetes-cases-projected-to-increase-worldwide-by-2049.aspx XX Early initiation of statins after a diagnosis of type 2 diabetes was associated with a lower risk of dementia, according to a study published in The Lancet Regional Health – Europe. According to the Lancet Commission, nearly half of dementia cases could theoretically be prevented by eliminating 14 risk factors. "Detecting and treating high levels of low-density lipoprotein cholesterol (LDL-C) from midlife is one such highlighted risk factor," From Danish registers, researchers identified 132,585 statin-naive individuals who developed type 2 diabetes from 2006 through 2019, with follow-up until the end of 2021.   Medical records were searched for diagnoses of all-cause dementia. A clone-censor-weight design was used to analyze dementia incidence in patients with no statin initiation within five years after diagnosis, in those with early statin initiation within one year and in those with late statin initiation between one and five years after diagnosis.   https://medicalxpress.com/news/2026-08-early-statins-diagnosis-diabetes-dementia.html   XX We are heartbroken over the loss of our friend Dolly Parton. Dolly was a beloved icon whose extraordinary generosity, warmth, and compassion touched countless lives, including those of the Children's Diabetes Foundation and the Barbara Davis Center for Diabetes. Her support of The Carousel Ball and Carousel of Hope Ball reflected her deep commitment to helping children and families affected by type 1 diabetes. Beyond her remarkable talent, Dolly will be remembered for the kindness and joy she shared so generously with others. Our hearts are with her family, friends, and all who loved her as we celebrate her extraordinary life and lasting legacy. She will be deeply missed.    

As AI inference costs have dropped by over 90%, enterprises are embedding data and intelligence at the core of their operating and business models, enabling always-on, global execution beyond human limits. How are these AI-first enterprises reorganizing around AI in practice, and under what conditions does this actually translate into long-term value for society? This is the full audio from a session at the Annual Meeting of the New Champions 2026 in Dalian, China on 23-25 June, 2026. Watch it here: https://www.weforum.org/meetings/annual-meeting-of-the-new-champions-2026/sessions/whats-the-intelligence-limit-for-ai-first-enterprises/ Speakers: Yuxiang Zhou, Chief Executive Officer, Black Lake Technologies, Michael Römer, Senior Partner and Global Co-Lead, Activate: Digital and Analytics, Kearney Joey Wat, Chief Executive Officer, Yum China Holdings, Inc. Sudip Roy, Co-Founder and Chief Technology Officer, Adaption Yang Yanqing, Director of Center for Education, Innovation and Sustainable Development, ShanghaiTech University Mehdi Ghissassi, Chief Product and Technology Officer, AI 71 Catch up on all the action from the World Economic Forum's Annual Meeting of the New Champions 2026 at wef.ch/amnc26 and across social media using the hashtag #AMNC26. Check out all our podcasts on wef.ch/podcasts:  YouTube: - https://www.youtube.com/@wef/podcasts Radio Davos - subscribe: https://pod.link/1504682164 Meet the Leader - subscribe: https://pod.link/1534915560 Agenda Dialogues - subscribe: https://pod.link/1574956552

Margery Kraus is the Founder and Executive Chairman of APCO Worldwide, a company she started in 1984 as a small subsidiary of a Washington, D.C. law firm and built into a global consultancy with roughly 1,200 people across 35 locations.Her story, though, starts much earlier. The child of immigrants whose family fled Nazi Europe, passed through Cuba and eventually rebuilt their lives in America, Margery grew up around resilience, risk and starting again.We talk about how that shaped the entrepreneur she became, why she refused to listen when people told her “you can't do that,” and what it was really like building a global company while raising a family.We also get into the 2004 management buyout that helped make APCO one of the world's largest majority women-owned consulting firms, how you step back from leading a company you built without really letting go, and what four decades advising some of the world's most influential leaders have taught her about who thrives under pressure and who doesn't.Recorded in Dalian, China, during the World Economic Forum's Annual Meeting of the New Champions, we also look at the world right now: China's place in the global economy, shifting trade relationships and what the rest of the world may be getting wrong about this moment.And then there's AI. Margery says it's the thing that keeps her up at night. For someone who has built a career and a business around human trust, judgment and relationships, I wanted to know why.A fascinating conversation with someone who has spent more than 40 years building, adapting and refusing to stand still.Special thanks to the World Economic Forum for bringing us together in Dalian.

In this episode of the NCS Podcast Hot Topics series, host Eric Lawson, MD, speaks with NCS Vice President and Annual Meeting Planning Committee Chair Lori Shutter, MD, FNCS, for a preview of the NCS 24th Annual Meeting, taking place Oct. 20-23 in Seattle. Dr. Shutter discusses this year's theme, "Reaching New Heights: Advancing the Future of Neurocritical Care," and how it reflects the Society's continued growth and optimism about the future of the field. The conversation offers a look at expanded workshop offerings, including sessions on the essentials of neurocritical care, critical care procedures, point-of-care and neurofocused ultrasound, and informatics and big data. Dr. Shutter also previews keynote addresses from Walter Koroshetz, MD, and Lisa Meeks, PhD, along with sessions focused on clinical trials, physiology, pediatric neurocritical care, global health, professional development and sustainability in the ICU. Listeners will also learn about opportunities for first-time attendees and new members, the return of the leadership closing panel and an open brainstorming session focused on the Society's next major area of research. Dr. Shutter shares how attendee feedback shaped this year's program and offers advice for making the most of the meeting's concurrent sessions, networking opportunities and special events. The views expressed on the NCS Podcast are solely those of the host and guest and do not necessarily reflect the opinions or official positions of the Neurocritical Care Society.

Recorded live at the ASGCT 2026 Annual Meeting in Boston, Le Cong, PhD joins hosts Jason West, PhD and Sanjay D’Souza, PhD for a discussion on his work in genome engineering and the early development of CRISPR/Cas9. The three then dive into Dr. Cong’s use of artificial intelligence tools developed and currently used by his lab. Dr. Cong is a 2026 recipient of ASGCT’s Outstanding New Investigator Awards. Music: ‘Bright New Morning’ by Steven O’Brien – released under CC-BY 4.0. https://www.steven-obrien.net/Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Global foreign direct investment rebounded by 14% to $1.6 trillion in 2025, yet the gains remained heavily concentrated in advanced economies, widening the gap with the emerging markets expected to drive the majority of growth in the coming decades. Young populations, rapid digital adoption and expanding consumer bases give emerging economies significant structural advantages, but capital, technology and industrial capacity continue to flow elsewhere. As competitiveness gaps widen, what is separating the front-runners from the laggards, and where will the next engines of growth emerge? This is the full audio from a session at the Annual Meeting of the New Champions 2026 in Dalian, China on 23-25 June, 2026. Watch it here:  https://www.weforum.org/meetings/annual-meeting-of-the-new-champions-2026/sessions/growth-map-rewritten/ Speakers:  A. Burak Dağlıoğlu, President, Investment Office of the Presidency of Türkiye   Elaine Yu, China Correspondent, CNBC Asia   Leslie Vinjamuri, President and Chief Executive Officer, Chicago Council on Global Affairs   Zou Ling, Founder of Honghub and Co-Head of Primavera Venture Partners, Primavera Capital Group   Aparna Bharadwaj, Global Leader, Global Advantage Practice; Managing Director and Senior Partner, Boston Consulting Group   Catch up on all the action from the World Economic Forum's Annual Meeting of the New Champions 2026 at wef.ch/amnc26 and across social media using the hashtag #AMNC26. Check out all our podcasts on wef.ch/podcasts:  YouTube: https://www.youtube.com/@wef Radio Davos - subscribe: https://pod.link/1504682164 Meet the Leader - subscribe: https://pod.link/1534915560 Agenda Dialogues - subscribe: https://pod.link/1574956552

Mazen S. Darwazeh is the Executive Chairman and Deputy Chief Executive Officer of Hikma Pharmaceuticals, and a Jordanian senator currently serving his fifth term.His journey with Hikma began in 1985 as a medical representative.Over the next four decades, he rose through the company to lead its MENA business and help shape Hikma into the largest pharmaceutical company by sales in the region and a FTSE 100 multinational employing around 9,500 people across three continents.Recorded in Dalian, China, this conversation was made possible thanks to the World Economic Forum, who facilitated the episode during the Annual Meeting of the New Champions.On this episode, we talk about what it takes to preserve the values of a family-built company as it becomes a global institution, Hikma's ambitions for healthcare in the Middle East, the growing role of biosimilars and biotechnology, and the challenge of ensuring access to essential medicines in a region shaped by geopolitical uncertainty.We also discuss China's evolving role in the pharmaceutical industry, Mazen's perspective from both business and public service, and what four decades in healthcare have taught him about leadership, longevity and building something that lasts.

What more should we know now about this country that is central to the global economy and is playing an ever greater role in geopolitics? Synopsis: Every second Friday of the month, The Straits Times’ senior columnist Ravi Velloor distils 45 years of experience covering the Asian continent, with expert guests. In this first-ever joint episode of Asian Insider and Radio Davos, he is joined by the World Economic Forum’s Robin Pomeroy as they speak with Qian Liu, whose Wusawa Advisory helps companies understand China. It was recorded in late June at the World Economic Forum’s Annual Meeting of the New Champions 2026 in Dalian, China. Ravi and Robin discuss with Qian about how a Chinese economy built on innovation and scale is impacting the world, the mainland’s internal worry lines such as high youth unemployment and lagging consumption, and why female power could drive China’s next growth phase. Highlights (click/tap above) 4:00 Exports, joblessness, property in a slowing economy 9:00 China’s property market prospects 11:10 ‘Ageing concubine’ Europe ‘cooking up’ negativity 15:00 EVs, cognac and bubble tea 19:40 You don’t need to get fat on Chinese ice-cream 23:10 ‘Involution’ and its imperatives 25:00 Shrugging off Hormuz 27:00 China’s watching US destroy itself 33:00 Female power in China More at wef.ch/amnc26 and across social media using the hashtag #AMNC26 Produced and edited by Radio Davos: Editing - Seamus Hart, Louie Carroll Studio production: Gareth Nolan --- Read Ravi's columns: https://str.sg/3xRP Follow Ravi on X: https://twitter.com/RaviVelloor Sign up for ST’s weekly Asian Insider newsletter: https://str.sg/sfpz Host: Ravi Velloor (velloor@sph.com.sg) Follow Asian Insider Podcast on Fridays here: Channel: https://str.sg/JWa7 Apple Podcasts: https://str.sg/JWa8 Spotify: https://str.sg/JWaX YouTube: https://str.sg/rF3qR Feedback to: podcast@sph.com.sg --- Follow more ST podcast channels: All-in-one ST Podcasts channel: https://str.sg/wvz7 Get more updates: http://str.sg/stpodcasts --- Get The Straits Times app, which has a dedicated podcast player section: The App Store: https://str.sg/icyB Google Play: https://str.sg/icyX --- Discover more Radio Davos podcasts:From 'US innovates, China imitates' to 'Opportunity 2.0' - lessons from Summer Davos: https://www.weforum.org/podcasts/radio-davos/episodes/strategic-intelligence-amnc26-debrief-china-innovation/The Hormuz shock, AI and China: the state of global energy, with Jason Bordoff: https://www.weforum.org/podcasts/radio-davos/episodes/amnc26-energy-china-hormuz-oil-gas-renewables-bordoff/AMNC26: What just happened at the Summer Davos?: https://www.weforum.org/podcasts/radio-davos/episodes/amnc26-what-just-happened-summer-davos/All podcasts: wef.ch/podcasts: YouTube: https://www.youtube.com/@wef/podcasts Radio Davos: https://pod.link/1504682164Meet the Leader: https://pod.link/1534915560Agenda Dialogues: https://pod.link/1574956552 --- #STAsianInsiderSee omnystudio.com/listener for privacy information.

What more should we know now about this country that is central to the global economy and is playing an ever greater role in geopolitics? Synopsis: Every second Friday of the month, The Straits Times’ senior columnist Ravi Velloor distils 45 years of experience covering the Asian continent, with expert guests. In this first-ever joint episode of Asian Insider and Radio Davos, he is joined by the World Economic Forum’s Robin Pomeroy as they speak with Qian Liu, whose Wusawa Advisory helps companies understand China. It was recorded in late June at the World Economic Forum’s Annual Meeting of the New Champions 2026 in Dalian, China. Ravi and Robin discuss with Qian about how a Chinese economy built on innovation and scale is impacting the world, the mainland’s internal worry lines such as high youth unemployment and lagging consumption, and why female power could drive China’s next growth phase. Highlights (click/tap above) 4:00 Exports, joblessness, property in a slowing economy 9:00 China’s property market prospects 11:10 ‘Ageing concubine’ Europe ‘cooking up’ negativity 15:00 EVs, cognac and bubble tea 19:40 You don’t need to get fat on Chinese ice-cream 23:10 ‘Involution’ and its imperatives 25:00 Shrugging off Hormuz 27:00 China’s watching US destroy itself 33:00 Female power in China More at wef.ch/amnc26 and across social media using the hashtag #AMNC26 Produced and edited by Radio Davos: Editing - Seamus Hart, Louie Carroll Studio production: Gareth Nolan --- Read Ravi's columns: https://str.sg/3xRP Follow Ravi on X: https://twitter.com/RaviVelloor Sign up for ST’s weekly Asian Insider newsletter: https://str.sg/sfpz Host: Ravi Velloor (velloor@sph.com.sg) Follow Asian Insider Podcast on Fridays here: Channel: https://str.sg/JWa7 Apple Podcasts: https://str.sg/JWa8 Spotify: https://str.sg/JWaX YouTube: https://str.sg/rF3qR Feedback to: podcast@sph.com.sg --- Follow more ST podcast channels: All-in-one ST Podcasts channel: https://str.sg/wvz7 Get more updates: http://str.sg/stpodcasts --- Get The Straits Times app, which has a dedicated podcast player section: The App Store: https://str.sg/icyB Google Play: https://str.sg/icyX --- Discover more Radio Davos podcasts:From 'US innovates, China imitates' to 'Opportunity 2.0' - lessons from Summer Davos: https://www.weforum.org/podcasts/radio-davos/episodes/strategic-intelligence-amnc26-debrief-china-innovation/The Hormuz shock, AI and China: the state of global energy, with Jason Bordoff: https://www.weforum.org/podcasts/radio-davos/episodes/amnc26-energy-china-hormuz-oil-gas-renewables-bordoff/AMNC26: What just happened at the Summer Davos?: https://www.weforum.org/podcasts/radio-davos/episodes/amnc26-what-just-happened-summer-davos/All podcasts: wef.ch/podcasts: YouTube: https://www.youtube.com/@wef/podcasts Radio Davos: https://pod.link/1504682164Meet the Leader: https://pod.link/1534915560Agenda Dialogues: https://pod.link/1574956552 --- #STAsianInsiderSee omnystudio.com/listener for privacy information.

Today, Thursday, August 13 on Urban forum Northwest:*Congressman Adam Smith (D) WA-09, Ranking Member, House Armed Services Committee comments on the current political climate in the country, the president's war with Iran, and on Tuesdays primary elections.*Dominique (Dom) Davis, Executive Director, Community Passageways comments on how his organization works with gang members including intervening before violence occurs. His organization funding has been cut and time of drastic need for intervention and training for participants in his program.*Roberto Jordan, president, Sundiata African American Cultural Association and Grady Austin, Executive Director, Festival Sundiata invites you to the August 22 & 23 FREE event that will be held at the Seattle Center. Experience Skate Sundiata, Sundiata Art Exhibit, Sundiata Marketplace, Taste of Sundiata, Sip Sundiata, and the Children's Museum.*Michelle Merriweather, CEO & president, Urban League of Metropolitan Seattle was honored by the National Urban League at the organization's Annual Meeting in Nashville, Tennessee last week with the Women of Power Award.Urban Forum Northwest streams live at www.1150kknw.com. Visit us at www.urbanforumnw.com for archived programs and relevant information. Like us on Facebook. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Featuring perspectives from Dr Wassim Abida, Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Rana R McKay, moderated by Dr McKay, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Antonarakis (2:42) Current and Future Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Aggarwal (26:23) Current and Future Role of Regimens Combining PARP Inhibitors and Androgen Receptor (AR) Pathway Inhibitors in Metastatic Prostate Cancer — Dr Abida (53:01) Emerging Role of AKT Inhibition for Patients with mHSPC — Prof Fizazi (1:17:22) Current and Future Use of Radiopharmaceuticals in Metastatic Prostate Cancer — Dr McKay (1:39:37) CME information and select publications

China is a partner and rival to many countries around the world. But what should we know about this country that is central to the global economy and is playing an ever greater role in geopolitics? On this joint episode of Radio Davos and Asian Insider, a podcast from the Singapore-based Straits Times, we speak to Qian Liu, whose company Wusawa helps advise companies understand China. Co-hosted by Ravi Velloor of Asian Insider: https://www.straitstimes.com/tags/asian-insider-podcast Produced and edited by: Editing - Seamus Hart, Louie Carroll. Studio production: Gareth Nolan. This was recorded at the World Economic Forum's Annual Meeting of the New Champions 2026. Catch up on that at wef.ch/amnc26 and across social media using the hashtag #AMNC26. About Straits Times Asian Insider: Channel: https://str.sg/JWa7 Apple Podcasts: https://str.sg/JWa8 Spotify: https://str.sg/JWaX Weekly Asian Insider newsletter: https://str.sg/sfpz  Related podcasts: From 'US innovates, China imitates' to 'Opportunity 2.0' - lessons from Summer Davos: https://www.weforum.org/podcasts/radio-davos/episodes/strategic-intelligence-amnc26-debrief-china-innovation/ The Hormuz shock, AI and China: the state of global energy, with Jason Bordoff: https://www.weforum.org/podcasts/radio-davos/episodes/amnc26-energy-china-hormuz-oil-gas-renewables-bordoff/ AMNC26: What just happened at the Summer Davos?: https://www.weforum.org/podcasts/radio-davos/episodes/amnc26-what-just-happened-summer-davos/ Check out all our podcasts on wef.ch/podcasts:  YouTube - https://www.youtube.com/@wef/podcasts Radio Davos - subscribe: https://pod.link/1504682164 Meet the Leader - subscribe: https://pod.link/1534915560 Agenda Dialogues - subscribe: https://pod.link/1574956552    

Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics: Introduction (0:00) The Biopathophysiology of Myelofibrosis (MF) (2:19) Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49) Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00) Upcoming at European Hematology Association (EHA) 2026 (49:22) CME information and select publications

What do you do when life changes in an instant—and the future you expected disappears? Advocate, activist and author Katie Piper explains how she rebuilt her life after surviving an acid attack on a London street at 24 driven by a man she'd briefly dated. The ordeal lead her to rethink her purpose, eventually founding a burn-rehabilitation charity and helping survivors like herself reframe "Why me?" as "What now?" It's a special conversation about resilience, personal reinvention and leading through adversity. You'll learn: -Why real confidence comes from knowing you can adapt and recover -The importance of accepting situations as they are, and releasing expectations -How to see challenge as a way to recommit to your purpose -How acceptance, discomfort and a self-authored identity can help you start again -Why vulnerability and empathy are strengths in leadership Katie Piper is a bestselling author, television presenter and founder of the Katie Piper Foundation, which supports burn survivors through rehabilitation. She is also a survivor of male violence and an advocate for people with burns and visible differences. This conversation explores resilience, purpose, trauma recovery, inclusive leadership and turning pain into purpose. Follow Meet the Leader on YouTube, Spotify or podcast apps, and subscribe for more conversations with people shaping the world This interview was recorded in January 2026 at the World Economic Forum's Annual Meeting in Davos Switzerland. About this episode Read - Book: Beautiful, Katie Piper: https://www.amazon.com/dp/0091940761?lv=shuf&channelId=500&plpRedirect=mhFallback Watch - Davos 2026 session: Scars of Survival: How I Rebuilt My Life: https://www.weforum.org/meetings/world-economic-forum-annual-meeting-2026/sessions/scars-of-survival-how-i-rebuilt-my-life/ Connect - Foundation: https://www.katiepiperfoundation.org.uk/ Related episodes: How to Face Uncertainty and Take Action: Lessons from a Blind Sailor's Pacific Crossing Listen here - Spotify: https://tinyurl.com/ypxt89hm Read here - Transcript:  https://tinyurl.com/2jrpf9km Watch here - YouTube: https://www.youtube.com/watch?v=KwKVbh71_QY    How to Focus on What Matters Most: 5 Leaders' Effective Strategies Listen here - Spotify: https://tinyurl.com/49h7kx6x Read here - Transcript: https://tinyurl.com/36b6s6b7  Nick Thompson, The Atlantic: Why one CEO sets 'non-goals' - and what ultramarathons taught him about focus and mental toughness Watch here - YouTube: https://youtu.be/Xh9PLsyptgAListen here - Spotify: https://tinyurl.com/bdbrspj7  Read here - Listen: https://tinyurl.com/mtdhe37w  Suleika Jaouad: Harnessing Creativity and Curiosity to Lead Through Uncertainty Listen here - Spotify: https://tinyurl.com/5dck884j  Read here - Transcript: https://tinyurl.com/bdh8ax4yWatch here - YouTube: https://www.youtube.com/watch?v=Ex-SlEoDaIw&vl=en  

Fertility & Sterility on Air is at the European Society of Human Reproduction and Embryology 42nd Annual Meeting in London (Part 2)! In this episode, our hosts Eve Feinberg, Kate Devine, and Yannick Hurni cover:  (00:56) Trends in first-cycle and cumulative live birth rates in the United States with Alexandra Herweck, SREI Landmark Articles podcast host (09:05) Impact of health optimization on reproductive outcomes and looking ahead to new REI innovations with Jim Toner, ASRM Vice President (20:07) Multiple sonographic markers of endometrial receptivity are significantly altered after hormonal intrauterine device (IUD) use among reproductive-aged women with proven fertility with Said Daneshmand (32:22) Effect of natural versus programmed cycle on the risk of hypertensive disorders of pregnancy following frozen-thawed blastocyst transfer: a randomized clinical trial in ovulatory women with Fang Gu (40:51) A look ahead to the 2026 ASRM Annual Meeting and impact of lifestyle factors on ART with Amy Sparks, ASRM President-Elect (47:19) Evaluating the safety and efficacy of IVF add-ons with Sarah Lensen (56:33) Clinical relevance of high-level mosaicism after PGT-A: mosaic segmental aneuploidies drive unexpected live birth outcomes with Francesca Spinella (01:06:23) Letrozole versus clomifene, with or without metformin, for ovulation induction in women with polycystic ovary syndrome (LOCI): a multicentre, 2x2 factorial design, randomised controlled trial with Pedro Melo View Fertility and Sterility at https://www.fertstert.org/  

Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics: Introduction (0:00) Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (SCLC) — Dr Shields (2:17) Management of Relapsed/Refractory SCLC — Dr Paz-Ares (33:24) Ongoing Investigation and Potential Role of Antibody-Drug Conjugates in SCLC — Dr Chiang (1:02:28) Management of Limited-Stage SCLC — Dr Ganti (1:31:54) CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Prof Eric Van Cutsem, moderated by Dr Janjigian, including the following topics: Introduction (0:00) HER2-Targeted Approaches in Advanced Gastroesophageal Cancers — Prof Van Cutsem (2:08) Targeting CLDN18.2 in Advanced Gastroesophageal Cancers — Dr Shah (30:54) Available Immunotherapeutic Strategies for Advanced Gastroesophageal Cancers — Dr Janjigian (1:01:39) CME information and select publications

What are state attorneys general preparing to tackle next—and what should businesses be watching? In this episode, we recap key takeaways from the 2026 Attorneys General Alliance Annual Meeting, where state AGs, regulators, and industry leaders focused on the rapid evolution of AI, privacy, pricing, child safety, and public-private partnerships. From growing scrutiny of algorithmic and surveillance pricing to expanding expectations around AI governance, data practices, online child protection, and collaboration between government and industry, the meeting underscored that state AGs are continuing to expand their influence across emerging technologies and consumer protection. For companies, the message was clear: proactive engagement, strong compliance programs, and a clear understanding of evolving state priorities will be essential as enforcement continues to accelerate. Hosted by Simone Roach. Based on a blog post by Paul L. Singer, Abigail Stempson, Beth Bolen Chun, and Andrea deLorimier.

Jonathan Haidt, author of The Anxious Generation, spoke to the World Economic Forum's Meet the Leader podcast at the Annual Meeting in Davos in January for an episode called "How leaders can fix focus and happiness in an AI Era". You can watch the interview here: https://www.youtube.com/watch?v=-bXp43TMMAI and find a transcript and more information here: https://www.weforum.org/podcasts/meet-the-leader/episodes/jonathan-haidt-happiness-focus-habits-ai/ Check out all our podcasts on wef.ch/podcasts:  YouTube: https://www.youtube.com/@wef Radio Davos - subscribe: https://pod.link/1504682164 Meet the Leader - subscribe: https://pod.link/1534915560 Agenda Dialogues - subscribe: https://pod.link/1574956552

Drs. Avni Finn and Matthew Starr join to discuss their favorite presentations and topics from the 2026 ASRS Annual Meeting.

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics: Introduction (0:00) Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22) Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31) Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24) CME information and select publications

Join Dr. Miho Tanaka and special guest Dr. Dan Wascher for a timely conversation recorded at the 2026 AOSSM Annual Meeting. In this bonus episode, they discuss Dr. Wascher's recently published article, "Artificial Intelligence Cannot Replace Peer Reviewers but May Help Editors Triage: A Comparative Analysis of a Large Language Model and Human Reviewer Recommendations at the American Journal of Sports Medicine," exploring how large language models (LLMs) may someday support—but not replace—the critical work of human peer reviewers.

(Please excuse any sound quality issues, as some interviews were recorded in a large hall where background noise and echoes were hard to avoid.) Fertility & Sterility on Air is at the European Society of Human Reproduction and Embryology 42nd Annual Meeting in London (Part 1)! In this episode, our hosts Micah Hill and Yannick Hurni cover:  (01:49) ASRM President Robert Brannigan on the effect of lifestyle factors on male fertility and a look ahead at the 2026 ASRM Annual Meeting (07:25) The 2-shot protocol: a randomised controlled trial of a novel two-injection ovarian stimulation strategy with Valeria Donno (14:49) Paired trophectoderm and ICM analysis redefines segmental aneuploidy and embryo usability in poor-prognosis IVF patients with Balsam Al Hashimi View Fertility and Sterility at https://www.fertstert.org/  

Featuring an interview with Dr Ramez Eskander, including the following topics: Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00) Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53) Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58) Current and investigational targets of ADCs in gynecologic cancers (17:14) Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56) Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36) Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34) Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05) Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38) CME information and select publications

In this episode recorded live at the ASGCT 2026 Annual Meeting in Boston, host Eirini Vamva, PhD interviews Anna Maurer, PhD of the University of Michigan. Dr. Maurer shares her story of growing up in Michigan and how her path led her to Harvard Medical School. She discusses her work in AAV and gives advice to individuals looking to enter the field of cell and gene therapy. Music: 'Dreamer' by Steven O'Brien – Released under CC-BY 4.0. https://www.steven-obrien.net/Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Tune in for the top 10 takeaways from the AAHFN 2026 Annual Meeting.

WITL Committee News and UpdatesJoin Ericka and Cassie for an update on all things Women in the Law Committee - WITL Power Hour Lunch and Learn Sessions, Summer Favorite Things Zoom Event, Annual Meeting, Mentorship Program, Upcoming Featured Post on DRI's social media, Speakers Workshop, Leadership and Publication Opportunities, and next year's San Diego, CA Conference. There is truly a place for everyone in this Committee and we are constantly hosting fun, informative, engaging, and inclusive programming for our committee members all year long. For more information about any of these topics, please contact the following:Lunch and Learn - Elizabeth Penn at elizabeth.penn@huschblackwell.comSummer Favorite Things - Jenifer Steinmetz at jennifer.steinmetz@tuckerellis.comMentorship Program, Annual Meeting, 2027 Conference, Leadership Openings, and Publication Opportunities - Jennifer Nutter at jennifer.nutter@hoodlaw.comSpeaker's Workshop - Sharon Stuart at sdstuart@csattorneys.com and Julie Fixmeyer at jfixmeyer@atllp.comAnd as always, tune in for our "Tell Me Something Good" segment.We would love for you to share this podcast with friends, subscribe to the DRI channel, and give us a rating and review. Thanks friends!To learn more about DRI and the Women in the Law Committee, visit www.DRI.org.#DRIWomenInTheLaw#DRILawyer#DRICommunity

Send us Fan MailWhat were some of the biggest metastatic breast cancer updates from the 2026 ASCO Annual Meeting and which findings are already changing care?In this episode of OUR MBC Life, Dr. Chen breaks down key research findings and what they mean for people living with metastatic breast cancer. This episode also includes a Q & A featuring questions from our community about treatment,  side effects and what these new advances mean for people living with metastatic breast cancer.We're so happy you joined us! If this conversation resonated with you please share it with someone who might need it. Don't forget to like and subscribe here to follow us on your favorite podcast platform so you never miss an episode. You can find more episodes, resources and ways to get involved on our website Our MBC Life. Have a topic you'd like us to cover? Email us at ourmbclife@sharecancersupport.org. And don't forget to follow us on our socials @ourmbclife. Remember you are not alone.

"Polycrisis" was a term coined to describe the convergence of multiple global challenges: political polarisation, conflicts, and the breakdown of post-World War Two norms on issues such as trade and security. Yuen Yuen Ang, a political science professor at Johns Hopkins University, says polycrisis was a useful way of framing the problem, but to find solutions we should consider the global "polytunity". This episode of Radio Davos was produced jointly with CNA Correspondent from Singapore-based Channel News Asia, and is co-hosted with CNA journalist Olivia Siong. https://www.channelnewsasia.com/listen/cna-correspondent This was recorded at the World Economic Forum's Annual Meeting of the New Champions 2026. Catch up on that at wef.ch/amnc26 and across social media using the hashtag #AMNC26. Related podcasts: From 'US innovates, China imitates' to 'Opportunity 2.0' - lessons from Summer Davos:  https://www.weforum.org/podcasts/radio-davos/episodes/strategic-intelligence-amnc26-debrief-china-innovation/ The Hormuz shock, AI and China: the state of global energy, with Jason Bordoff:  https://www.weforum.org/podcasts/radio-davos/episodes/amnc26-energy-china-hormuz-oil-gas-renewables-bordoff/ AMNC26: What just happened at the Summer Davos?: https://www.weforum.org/podcasts/radio-davos/episodes/amnc26-what-just-happened-summer-davos/ Check out all our podcasts on wef.ch/podcasts:  YouTube - https://www.youtube.com/@wef/podcasts Radio Davos - subscribe: https://pod.link/1504682164 Meet the Leader - subscribe: https://pod.link/1534915560 Agenda Dialogues - subscribe: https://pod.link/1574956552

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Stacey A Cohen and Dr Arvind Dasari, moderated by Dr Bekaii-Saab, including the following topics: Introduction (0:00) Current and Future Role of Immune Checkpoint Inhibition in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Localized and Locally Advanced Colorectal Cancer (CRC) — Dr Cohen (1:45) Clinical Relevance and Practical Utilization of Molecular Residual Disease Analysis in CRC — Dr Dasari (34:08) Recent Advances in Metastatic CRC: Optimizing Immunotherapy and Other Approaches — Dr Bekaii-Saab (1:00:42) CME information and select publications

The future of sports medicine isn't shaped solely in the operating room—it is also driven by visionary leadership, collaboration, education, and innovation. Live from the AOSSM Annual Meeting in Seattle, Drs. Catherine Logan and Ashley Bassett sit down with Corey Parker, MPA, the newly appointed CEO of the American Orthopaedic Society for Sports Medicine (AOSSM), to discuss his vision for one of the world's leading sports medicine organizations.With more than two decades of executive leadership experience in healthcare, academic medicine, and national physician organizations, Corey shares what drew him to AOSSM and how he plans to help the society continue advancing education, research, advocacy, and member engagement in an era of rapid change.The conversation explores how AOSSM is preparing surgeons for emerging technologies like artificial intelligence and biologics, expanding mentorship and leadership opportunities for early-career members, and strengthening collaboration across the multidisciplinary sports medicine team. Corey also discusses the importance of serving both academic and private practice surgeons while ensuring the organization remains innovative, financially strong, and increasingly valuable to its members.Whether you're a resident just beginning your career or a seasoned sports medicine surgeon, this episode offers an inside look at the leadership shaping the future of our specialty.In This Episode Corey Parker's journey to becoming CEO of AOSSM  Why AOSSM continues to be a global leader in sports medicine  Supporting residents, fellows, and early-career surgeons through mentorship and leadership development  Strengthening connections between academic and private practice sports medicine physicians  Developing the next generation of leaders within AOSSM  Building stronger partnerships across the sports medicine care team  Corey's vision for the future of AOSSM and the legacy he hopes to leave Key Takeaways Leadership is essential to advancing sports medicine beyond clinical innovation.  Lifelong education and evidence-based guidance remain central to helping surgeons navigate an evolving field.  Mentorship and early career engagement are critical investments in the future of the specialty.  Collaboration across physicians, therapists, athletic trainers, researchers, and industry drives better patient care.  A strong professional society must continue evolving while remaining focused on its mission and its members. About Our GuestCorey Parker brings more than 20 years of progressive executive leadership in healthcare, academic medicine, and national medical societies. He currently serves as Chief Operating Officer of the American Association of Neurological Surgeons, where he oversees a complex enterprise of 65 staff and a combined operating budget exceeding $30 million. Previously, he served as Executive Director of Surgical Accreditation at the Accreditation Council for Graduate Medical Education, where he led accreditation efforts for orthopedic surgery and other surgical specialties nationwide. Earlier leadership roles within major academic health systems further reflect his expertise in operational excellence, financial stewardship, and large-scale team development.Parker will join the AOSSM professional team on April 6, 2026. He succeeds CEO Greg Dummer, who announced his intent to retire last August. Dummer has served as CEO since July 2016 and will remain with the organization through the 2026 Annual Meeting to support a smooth and successful transitionFollow The Sports Docs Podcast for conversations with leading surgeons, researchers, and innovators who are advancing the field of sports medicine through cutting-edge science, education, and collaboration.https://www.cloganmd.com/https://orthopedicnj.com/physicians/ashley-bassett

Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O'Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics: Introduction (0:00) Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35) Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O'Shaughnessy (25:23) Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29) Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06) Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17) CME information and select publications

Hugh continues to broadcast live from the ALEC 2026 Annual Meeting from Orlando Florida, talking with: Texas State Senator Phil King, ALEC Board Member Florida State Representative Demi Busatta, 2026 ALEC National Chair Missouri Senator State Ben Brown Kentucky State Representative Kim Moser Iowa Speaker Pro Tem John Wills Jonathan Williams, ALEC President, Chief Economist California Assemblyman David Tangipa Texas State Representative Caroline Harris Davila Texas State Senator Adam Hinojosa Florida State Representative John Snyder See omnystudio.com/listener for privacy information.

Hugh broadcasts live from the ALEC 2026 Annual Meeting from Orlando Florida, talking with: Lisa Nelson, ALEC CEO TJ Shope, Arizona Senate President Pro Tem, ALEC Board Member Patricia Rucker, West Virginia Senator Assistant Majority Leader, 2025 ALEC National Chair Chris Croft, Kansas House Majority Leader Rob McColley, Ohio Senate President, Lt. Governor candidate Julie Daniels, Oklahoma Senate Majority Floor Leader Michigan House Speaker Matthew Hall, ALEC Board Member Arkansas State Senator Jim Dotson, incoming ALEC chair Jon Brien, Rhode Island Representative, Public Sector Chair of ALEC Process & Procedures Task Force Texas Senator Paul Bettencourt, ALEC State Chair See omnystudio.com/listener for privacy information.

Featuring perspectives from Dr Sarah B Goldberg, Dr Jonathan Goldman, Dr Joel W Neal, Dr Antonio Passaro and Dr Jacob Sands, moderated by Dr Sands, including the following topics: Introduction (00:00) Evolving First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Prof Passaro (2:27) EGFR-Targeted Therapeutic Strategies for Relapsed EGFR-Mutant NSCLC — Dr Neal (36:08) Utility of TROP2-Targeted Antibody-Drug Conjugates in the Management of EGFR-Mutant NSCLC — Dr Sands (56:16) Emerging Role of Bispecific Antibody-Based Approaches for EGFR-Mutated NSCLC — Dr Goldman (1:19:08) Tolerability Considerations with the Use of Available and Emerging Therapies for EGFR-Mutated NSCLC — Dr Goldberg (1:38:46) CME information and select publications

Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics: Introduction (0:00) Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45) Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55) Potential Role of Cereblon E3 Ligase Modulators in Therapy for MM — Dr Richardson (59:42) Chimeric Antigen Receptor T-Cell Therapy for R/R MM — Dr Alsina (1:30:24) CME information and select publications

New Brunswick Premier Susan Holt joins us from PEI where provincial and territorial leaders have put aside their annual meeting agenda to focus on the threat of new 50 per cent tariffs from the US. She tells us how this could impact her province and what leaders will ask of the Prime Minister as they set to meet with him later today.

Dr. Imogene Drakes is a career scientist, spiritual researcher, and international speaker. She grew up in Guyana's multicultural society before moving to the United States in 1989. Her early passion for science led to a journey that would take her across six continents in search of the truth about religion, mythology, and science. Dr. Drakes managed clinical and forensic analyses in Guyana and served as lecturer for the Guyana Police Academy. After relocating to the US, she worked in clinical laboratory science, retiring as a Laboratory Director in 2025. Her diverse interests include teaching public health at SUNY Downstate, singing in a gospel choir, and volunteering as a board member in her community. Dr. Drakes has been recognized for outstanding community service and has presented at major medical society meetings, including as the opening presenter of the 2024 Annual Meeting of the Vermont Medical Society. Dr. Drakes is the author of "Around the World in 42 Days". In episode 692 of the Fraternity Foodie Podcast, we find out what lessons from her multicultural upbringing continues to shape her worldview today, what were the key decisions that shaped your professional path, what inspired her to take a solo journey through 10 countries and 11 ancient sites in just 42 days, what her travels taught her about uncertainty and self-discovery, how college students can find meaning and growth even if they don't have the resources to travel around the world, what are some simple techniques students can use when they're feeling overwhelmed, how to pause when feeling peer pressure and make better decisions in those moments, how to create cultures where people feel safe speaking up when something doesn't feel right, an example of public health achievements that came through laws and policies that most people never think about, and questions about life and purpose students are asking today that she thinks deserve more attention. Enjoy!

DRWarner Bros.' Zaslav Offers $68 Million to Buy Summer Campnew January 2026 employment agreement$96M: Make-Whole RSU award to CEO Daivd Zaslav of 1,963,465 shares; after January 2 Follow-On Option award of 3,052,734 options because share price is downUnder a new employment agreement executed on June 12, 2025, Zaslav received a special award of 20,898,776 stock options with an exercise price of $10.16 (~$400M). Additionally, on January 2, 2026, he was granted 3,052,734 follow-on stock options with an exercise price of $28.51 (~$40M). To address the higher exercise price of these options compared to the initial grant, Zaslav received 1,963,465 restricted stock units on January 5, 2026 (~$56M).The Compensation Committee: 23 meetings in 2025*Paul A. Gould, 80, 18 years tenureGould and Zaslav worked closely together at Discovery, Inc. for nearly 15 years.David Zaslav took the helm as President and CEO of Discovery, Inc. in January 2007.Paul Gould joined the Discovery, Inc. Board of Directors shortly after, serving as an independent director from 2007 until the company merged with WarnerMedia.Both men belong to the tight-knit professional circle surrounding cable pioneer and billionaire John Malone.Paul Gould has a long history as a trusted director across Malone's web of companies, serving for years on the boards of Liberty Global and Liberty Latin America.David Zaslav has publicly and frequently cited John Malone as his primary professional mentor.Their shared ties to Malone are so closely linked that in 2012, Zaslav partnered with other high-level executives to donate $1 million to the Cable Center specifically to build and name the John Malone Theater.Paul Gould has served as a Managing Director and Executive Vice President at Allen & Company, a premium boutique investment bank deeply embedded in the media and entertainment ecosystem. Through this avenue, Gould and Zaslav connect in two ways:Financial Advisory: Allen & Company has a long history of providing valuation opinions, advisory services, and market analysis for major transactions initiated by Zaslav during his career.The Sun Valley Conference: Allen & Company famously hosts the annual "Summer Camp for Billionaires" in Sun Valley, Idaho. As a prominent media mogul, Zaslav is a regular, high-profile attendee at this event, which is organized by Gould's firm.Kenneth W. LoweKen Lowe is the former Chair/CEO of Scripps Networks Interactive (the former parent company of massive lifestyle brands like HGTV, Food Network, and ID).The Link: In 2018—four years before the Warner Bros. deal even closed—Zaslav orchestrated Discovery's $14.6 billion acquisition of Scripps Networks. As a direct result of that blockbuster cable industry consolidation, Lowe joined Discovery Inc.'s board of directors. He and Zaslav had already been working together closely at the board level for years before the legacy company expanded into WBD.The board of AT&TRichard W. FisherOutside of WBD, Zaslav's connection to Fisher is rooted in Fisher's previous role as a member of the Board of Directors for AT&T. When Zaslav was hammering out the complex transaction to spin WarnerMedia away from AT&T, Fisher was one of the crucial board leaders on the other side of the table who evaluated and signed off on the deal. As part of the closing agreement, Fisher was designated by AT&T to transition directly over to the new WBD board.Debra L. LeeDebra Lee was the longtime Chair/CEO of BET Networks (Black Entertainment Television) from 2006 to 2018.Zaslav and Lee have long-standing commitments to The Paley Center for Media, sharing space as members of its highly prestigious Board of Trustees. Additionally, Lee served on the board of AT&T, meaning she was part of the corporate governance team that initially approved Zaslav's pitch to merge Discovery with WarnerMedia.Geoffrey Y. YangJust like Richard Fisher and Debra Lee, Yang's primary pre-WBD connection to Zaslav comes down to AT&T. Yang sat on AT&T's board during the high-stakes dealmaking window. Because of his background in digital media and venture capital, he was designated by AT&T leadership to transition to the WBD board to help Zaslav steer the newly formed company's streaming and direct-to-consumer technology strategies.The board that ignores Say on Pay votesAt our 2025 Annual Meeting held on June 2, 2025, we held an advisory vote on executive compensation, or "Say on Pay" vote, and a majority of the votes cast by stockholders were cast against our executive compensation program.Our executive compensation program is designed to pay for performance and effectively balance executive and stockholder interests. The Committee considered the outcome of the "Say on Pay" vote from the 2025 Annual Meeting, and while it continues to believe that our executive compensation structure, which includes long-term agreements with each of our NEOs and delivers a significant majority of NEO compensation in performance-based vehicles, is effective in meeting our compensation objectives, it took note of the negative 2025 "Say on Pay" vote when making compensation decisions after the 2025 Annual Meeting.The Dodd-Frank Act: "The shareholder vote … shall not be binding on the issuer or the board of directors of an issuer, and may not be construed as overruling a decision by such issuer or board of directors”Special meeting vote 4/23/26: Say on Pay 83% no6/9 AGM: ShareholdersPaul A. Gould 52% noRichard W. Fisher 31% noDebra L. Lee 32% noKenneth W. Lowe 31% noGeoffrey Y. Yang 31% noZaslav 3% noSay on Pay 84% noStill on boardPaul A. GouldRichard W. FisherDebra L. LeeKenneth W. LoweGeoffrey Y. YangZaslavThe SEC: "The Say-on-Pay … votes are advisory rather than binding ... Unlike a binding vote, advisory votes do not require the company or its board of directors to take a specific action. The company's board of directors may consider advisory votes and may follow up with other communications or dialogue with shareholders as part of its deliberative process in making policy decisions."The workers for being poor1,378 to 1 CEO pay ratio.Andrew M. Cuomo Joins the OKX Board of DirectorsThe worldMen GreedThe U.S. Department of Justice (DOJ) In February 2025, OKX pled guilty in a U.S. federal court to operating an unlicensed money transmitting business and violating anti-money laundering (AML) laws.The U.S. Department of Justice (DOJ) revealed that despite OKX having an "official policy" banning U.S. users, the exchange actively pursued U.S. customers and generated hundreds of millions in fees from them.Internal logs showed OKX employees explicitly telling U.S. clients how to bypass the exchange's own blocks—even telling a customer to "just put a random country" during identity verification.The exchange was used to facilitate over $5 billion in suspicious transactions and criminal proceeds, resulting in a staggering $504 million penalty.TrumpTrump has normalized crypto. Is it the path to the next financial collapse?Jon Ossoff Rips RFK Jr.'s ‘Foolish' Cutback To Cyclosporiasis Monitoring: Sen. Jon Ossoff says a cyclosporiasis outbreak spreading nationwide could be harder to track because the Trump administration changed CDC surveillance last year. In a letter to Health Secretary Robert F. Kennedy Jr., Ossoff argues that the CDC's FoodNet program (a public health network that monitors infections from multiple pathogens across CDC, USDA, FDA, and 10 states) stopped requiring monitoring cyclospora, and that the administration later made data collection optional at FoodNet sites for most pathogens (except Salmonella and E. coli).Elon Musk"ESG is the devil"A "scam" weaponized by "phony social justice warriors"Vivek RamaswamyThe author of Woke, Inc.founded an entire asset management firm (Strive) designed explicitly to offer "anti-woke" investment options that ignore ESG metrics in favor of pure profit.Ron DeSantisSpearheaded a massive legislative pushback against ESG in Florida, signing bills that banned state and local governments from using ESG factors when investing public funds or issuing bondsArgues ESG is a way to bypass voters and enforce a political agenda through corporate power.Peter ThielCalled ESG a "hate factory" used to control capital and punish companies that don't fall in line with mainstream corporate ideologyTariq Fancy (Former Head of Sustainable Investing at BlackRock)“Whistleblower”Called ESG a "dangerous placebo" that does nothing to actually fix the planet but allows Wall Street to charge higher fees while greenwashing their portfoliosMike PenceArgues that major Wall Street firms use ESG to enforce a radical left-wing agenda on everyday Americans, forcing companies to adopt policies that hurt the domestic energy sector.Glenn Hegar (Texas Comptroller)Created a blacklist of financial companies (including BlackRock) banned from doing business with the state of TexasCalled ESG an "opaque and perverse system" that violates fiduciary dutyAndy Puzder (Former CEO of CKE Restaurants/Hardee's and Carl's Jr.)Argued that forcing companies to focus on social goals instead of profits violates shareholder capitalism and ultimately hurts the economySenator Tom CottonAttacked ESG from a legal and regulatory standpoint. He led a group of Republican senators in warning top U.S. law firms that advising companies to cooperate on ESG goals could open them up to massive federal antitrust violationsSanjai Bhagat (Finance Professor, University of Colorado)Argues that ESG funds don't actually deliver higher returns and that companies in ESG portfolios often have worse compliance records for labor and environmental rules than standard companiesMenI pay my employees $1,000 a month per child for day care. It's one of my ice cream company's best investments.A womanAll womenDEIMolly Moon Neitzelfounder and CEO of Molly Moon's Homemade Ice CreamHer business planwhich included living wages and free health insurance for everyone who worked at least 18 hours a weekMMC-suite promotions now come with three or more jobs - from the article: “When Target named Michael Fiddelke CEO in February 2026, the leadership changes he announced went beyond a standard promotion. Target eliminated its chief commercial officer role and consolidated merchandising authority into a single position, naming Cara Sylvester, previously chief guest experience officer, as the sole chief merchandising officer overseeing product development, assortment design, and partner collaborations.” - WHO DO YOU BLAME??AIIsn't “taking more jobs on” what the promise of AI has been? The article claims “Executives who excel in a specific function are increasingly entrusted with broader operating mandates spanning commercial, technology, operations, finance, or customer strategy” - but really, aren't we just admitting that marketing and sales can be done by a dopey robot?Executive ChairsAs the TOP boys realize they can offload their work by becoming Executive Chair (same salary, fewer hours, no responsibilities!), maybe the CEO class is realizing THEY can stop doing as much if they just give more jobs to underlings? It seems telling the prime example in the article is Target where Brian Cornell still lingers on the board like a boilPay committeesPay committees are handing out massive golden hellos, particularly to CFOs but all c-suite, and they can justify them by “rolling” pointless jobs into a single person, right? BoardsBoards aren't actually paying attention to executives anyway - the data suggests by and large boards in the US are either deferential to the executives (do whatever you want!) or entirely self dealing (highly connected horse trading jobs on other boards!). The result is an indifferent board to actual executive shakeups either way - and CEOs are using indifference to shake up the c-suitesGeneral Mills is recalling nearly 736,000 Pillsbury bread rolls over possible glass - WHO DO YOU BLAME??Public Responsibility Chair Jorge UribeEx “productivity” officer at P&G until he retired in 2015. MBA and bachelor's in “management engineering”, which confused our knowledge typing which pinged off “engineering” to give him Public Safety knowledge, but there's no ACTUAL EVIDENCE he did anything but sales/marketing10 year tenure - longer than the CEO, but not as long as…Longest tenured director and man on Public Responsibility committee Steve OdlandOdland is the CEO of the Conference Board, who does public policy and governance stuff - he was CEO of Office Depot and AutoZone, and came from food (Quaker Oats, Sara Lee)Been on the board 22 years!! Solid job if you can get itBut both Steve and Jorge are tagged as “deferential” in the data (this is an important gig for them), so maybe…CEO Jeff HarmeningWith General Mills since 1994, came from marketing, but was COO - maybe Jeff's job as a director at Toro Company made him too busy to notice the glass? Or, maybe it wasn't their fault at all…RFK Jr: It's not just Taco Bell lettuce and possible glass in Pillsbury rolls: Food and drink recall events reached a 6-year year-over-year high

The business session of the 88th meeting of Nolin RECC members held on June 18, 2026 in the Cooperative Meeting Center at the Nolin RECC office in Elizabethtown, KY. 

Featuring perspectives from Dr Floor J Backes, Dr Brian M Slomovitz and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Introduction (00:00) Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC) — Dr Backes (1:50) Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC — Dr Westin (33:15) Promising Agents Under Investigation for EC — Dr Slomovitz (1:01:41) CME information and select publications

Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics: Introduction (00:00) Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40) Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41) Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12) Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35) Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39) CME information and select publications

Send us Fan MailJoin host Christina K. Hardesty, MD, as she sits down with W.G. Stuart Mackenzie, MD, and Kariman Abelin-Genevois, MD, PhD, co-chairs of the 61st Annual Meeting, taking place October 6–10, 2026, in Sydney, Australia Tune in as they dive into this year's “Bridges and Transitions” theme, share highlights from the educational and scientific program, and preview some of the exciting speakers joining us in Sydney!Register today! Online registration closes September 15, 2026.*The Scoliosis Research Society (SRS) podcast is aimed at delivering the most current and trusted information to clinicians that care for patients with scoliosis and other spinal conditions. From news in the world of spinal conditions, to discussions with thought leaders in the field, we aim to provide up-to-date, quality information that will impact the daily practice of spinal conditions.

Recorded on site at the ASGCT 2026 Annual Meeting in Boston, host Sanjay D’Souza, PhD, talks with Fyodor Urnov, PhD, about the evolution and future of gene editing. One of the 2026 ASGCT Catalyst Award co-recipients, Dr. Urnov, talks about his work in gene editing and discusses the need for collaboration in the field to bring more cell and gene therapies to patients. Music: ‘Bright New Morning’ by Steven O’Brien – released under CC-BY 4.0. https://www.steven-obrien.net/Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

CPSolvers: Anti-Racism in Medicine Series Episode 30 – Mobile Health Clinics and Democratizing Healthcare: Live from the Society of General Internal Medicine (SGIM) Annual Meeting 2026 Show Notes by Alec J. Calac and Ashley Cooper July 13, 2026 Summary: In this episode, Dr. Shahid Jaffer and Dr. Priya Sarin Gupta join CPSolvers host Ashley Cooper for… Read More »Episode 466: Antiracism in Medicine – Episode 30 – Mobile Medical Clinics and Democratizing Health Care: Live from the Society of General Internal Medicine's 2026 Annual Meeting

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics: Case: A woman in her late 60s presents with mismatch repair-deficient metastatic endometrial cancer(00:00) Perspectives on neoadjuvant immunotherapy for microsatellite instability-high endometrial cancer (06:25) CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics: Case: A woman in her late 70s with de novo metastatic mismatch repair-proficient metastatic endometrioid endometrial cancer (00:00) Molecular analyses in the assessment and management of endometrial cancer (07:33) CME information and select publications

This week on Sinica, in a special episode recorded at the Davos On Air booth at the World Economic Forum's Annual Meeting of the New Champions in Dalian, I sat down with Angela Huyue Zhang, professor of law at USC's Gould School of Law and author of High Wire: How China Regulates Big Tech and Governs Its Economy, and S. Alex Yang, professor of management science and operations at London Business School. Angela and Alex — who are also married, and who arrived at this collaboration from opposite ends of the academy — have developed what I think is one of the most useful new mental models for understanding China's political economy: the platform state. Their argument is that we should think of the Chinese state less as a central planner or owner and more as a platform company like NVIDIA or Apple, one that builds architecture, sets standards, and governs an ecosystem within which fiercely competitive private firms fight it out. Value accrues at the system level rather than as firm profit, and the payoff may decide who wins the race to put AI to work across an entire economy.5:37 – Three puzzles the framework is built to solve: profitless dominance in solar, EVs, and batteries; why the "grabbing hand" hasn't strangled Chinese innovation; and how China is attempting both zero-to-one invention and one-to-hundred scaling at once7:57 – The platform state thesis: why the Chinese government behaves like a platform company, how nurturing an ecosystem of private firms solves the information deficit that cripples command-and-control, and why over-entry, involution, and consolidation are a repeated pattern — from EVs to the 140-plus humanoid robot companies operating today16:13 – The aha moment: how a paper on the legal infrastructure of physical AI became the platform state idea over the Zhang-Yang dinner table, and whether this is a new species of political economy or the East Asian developmental state in new clothes20:44 – State conditions: why state capacity and domestic scale are the two preconditions for the model, and why an ambitious Vietnam — which has the top-down capacity — may still find the Chinese playbook impossible to replicate23:39 – Profitless dominance by design: harvesting versus extracting, the Uber analogy, overshooting as a control-theory strategy for nudging sectors, and how the anti-involution campaign and the 60-day supplier payment mandate show the state moderating the very competition it engineered30:33 – Organized chaos: from the bike-sharing graveyards of the O2O wars to today's disciplined market, the exit of more than 400 EV makers since 2018, and why the survivors of China's "Premier League" of competition are now turning profitable32:59 – The 3Gs playbook: growing markets by solving the cold-start problem, from Liuzhou's EV test drives to Beijing's green license plates, and how subsidy is only one lever among many38:36 – Governing the ecosystem like Apple runs its App Store: why Beijing regulates generative AI with a light touch but physical AI is a different species entirely, law as the sixth layer of the AI stack, why robotaxis scale faster in China than in the U.S., and the state-convened standard-setting that's driving down humanoid robot costs46:54 – Two flywheels: the familiar data-and-cost flywheel and the deeper state capacity flywheel, and how the National AI Fund's small but voting stake in DeepSeek aligns a complementor with the domestic stack — tilting the ecosystem toward Chinese chips53:28 – Guarding the moat: automotive data rules and Tesla's stalled FSD ambitions, the unwound Manus sale, China's own small yard and high fence, and the closing provocation — that America could build the smartest frontier models and still lose the diffusion race to "artificial good-enough intelligence." Plus: the case for coopetition, and what policymakers should (and shouldn't) borrow from the platform stateLinks from the episodeAngela's paper on law as the sixth layer of China's AI stack:The Sixth Layer: The Legal Infrastructure for Physical Artificial Intelligence in China (SSRN)Three Project Syndicate op-eds on the platform state idea:The Rise of the Chinese Platform State by S. Alex Yang & Angela Huyue ZhangAre Government Stakes the Key to AI Sovereignty? by Angela Huyue ZhangOvercapacity Is China's Biggest AI Advantage by Angela Huyue ZhangTwo Management Science papers on commercial platforms:Crowd-Judging on Two-Sided Platforms: An Analysis of In-Group BiasImproving Dispute Resolution in Two-Sided Platforms: The Case of Review BlackmailSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this must-listen episode, Dr. Ryan Moenster is joined by Dr. Monica Mahoney and Dr. Mark Gilchrist to dive deep into the evolving landscape of outpatient parenteral antimicrobial therapy (OPAT) and complex outpatient antimicrobial therapy (CoPAT), highlighting real-world challenges, patient selection, and emerging treatment strategies. Navigating outpatient antimicrobial management can be complex, but this episode breaks down key insights and practical applications to help clinicians optimize care beyond the hospital. References: 1.       Noble AL, Patel S, Birnie E, et al. 2026 updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK. JAC Antimicrob Resist. 2026;8(2). 2.       British Society for Antimicrobial Chemotherapy (BSAC). OPAT Global Summit 2027. 3.       Naicker S, Roberts JA, Cheng V, et al. A review of antimicrobial stability testing guidance for outpatient parenteral antimicrobial therapy programmes: Is it time for global harmonization of testing frameworks? JAC Antimicrob Resist. 2024;6(6). 4.       Gilchrist M, Jamieson C, Drummond F, et al. Assessment of ceftolozane/tazobactam degradation profile and toxicity data in elastomeric devices for continuous infusion via outpatient parenteral antimicrobial therapy (OPAT). JAC Antimicrob Resist. 2023;5(2). 5.       Naicker S, Roberts JA, Won H, et al. Evaluation of the stability of ceftazidime/avibactam in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy utilizing a national stability protocol framework. JAC Antimicrob Resist. 2024;6(2). 6.       Wolie ZT, Unwin S, Burke A, et al. Evaluation of the stability of tigecycline in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy. JAC Antimicrob Resist. 2025;7(3). 7.       Solomon DA, Beieler AM, Levy S, et al. Perspectives on the use of outpatient parenteral antibiotic therapy for people who inject drugs: Results from an online survey of infectious diseases clinicians. Open Forum Infect Dis. 2023;10(7):ofad372. doi:10.1093/ofid/ofad372. 8.       Yagnik KJ, Brown LS, Saad HA, et al. Implementation of IV push antibiotics for outpatients during a national fluid shortage following Hurricane Maria. Open Forum Infect Dis. 2022;9(5):ofac117. doi:10.1093/ofid/ofac117. 9.       Boettcher SR, Kenney RM, Everson NA, et al. Discharge delays and costs associated with outpatient parenteral antimicrobial therapy for multidrug-resistant organisms: A retrospective cohort study. Open Forum Infect Dis. 2025;13(1):ofaf770. 10.   Rivera CG, Mara KC, Mahoney MV, Ryan KL. Survey of pharmacists on their roles and perceptions of outpatient parenteral antimicrobial therapy in the United States. Antimicrob Steward Healthc Epidemiol. 2022;2(1):e69. 11.   Rapoport AB, Fischer LS, Santibanez S, et al. Infectious diseases physicians' perspectives regarding injection drug use and related infections—United States, 2017. Open Forum Infect Dis. 2018;5(7):ofy132. doi:10.1093/ofid/ofy132. 12.   Turner NA, Hamasaki T, Doernberg SB, et al.; Antibacterial Resistance Leadership Group. Dalbavancin for treatment of Staphylococcus aureus bacteremia: The DOTS randomized clinical trial. JAMA. 2025;334(10):866–877. doi:10.1001/jama.2025.12543. 13.   Volk CF, Hutson PR, Rose WE. Simulated target attainment of multidose regimens of dalbavancin for prolonged durations of therapy. Open Forum Infect Dis. 2024;11(6):ofae315. doi:10.1093/ofid/ofae315. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Instagram: @SIDPharm ( https://www.instagram.com/sidpharm/) or @breakpointspodcast_sidp (https://www.instagram.com/breakpointspodcast_sidp/) https://www.instagram.com/breakpointspodcast_sidp/?hl=en Facebook: https://www.facebook.com/sidprx LinkedIn:  https://www.linkedin.com/company/sidp/ SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Recorded live from the Davos on Air booth at the World Economic Forum's Annual Meeting of the New Champions in Dalian, this special episode of Sinica tackles the "pacing problem": the widening gap between how fast AI moves and how slowly regulation can catch up. I sit down with Xue Lan, dean of Schwarzman College at Tsinghua University and one of the architects of China's concept of "agile governance," to unpack what that term means in practice. He traces China's regulatory evolution from the 2017 AI plan through the generative AI rules and the 2021 tech crackdown, compare Chinese, American, and European approaches, and ask whether Beijing's adaptive style can travel to other political systems — including liberal democracies.00:09 – Live from Dalian: the “pacing problem” and why AI has turned it into a chasm03:18 – Introducing Xue Lan, dean of Schwarzman College and architect of “agile governance”04:34 – Why AI's pace makes it uniquely hard to regulate06:01 – Defining agile governance: mindset, partnership over adversary, and light-touch tools11:54 – From the 2017 AI plan to today: China's two-track approach to tech and governance20:07 – Balancing development and security amid the US-China AI race23:24 – Revisiting the 2021 tech crackdown: failure of the model, or agility of a different kind?26:14 – The “DeepSeek moment,” open-weight models, and regulatory uncertainty by design37:10 – EU comprehensiveness vs. US patchwork vs. China's modular, adaptive approach46:59 – Can agile governance travel to liberal democracies? Finding common ground on global AI riskSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.